Antitumor activity of TZT-1027 (soblidotin)

Anticancer Research

Volumn 26, Issue 3 A, 2006, Pages 1973-1981

  Watanabe, Junichi ^a   Minami, Megumi ^b   Kobayashi, Motohiro ^a  

^a Grelan Pharmaceutical Co   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Cell killing kinetics; Fibrosarcoma Meth A; Multidrug resistance; Soblidotin; Tubulin inhibitor; TZT 1027

Indexed keywords

AURISTATIN PE; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DNA FRAGMENT; DOCETAXEL; DOLASTATIN 10; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; SOBLIDOTIN; UNCLASSIFIED DRUG; VINCRISTINE; ZINOSTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CELL KILLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG INHIBITION; ELECTROPHORESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL DEATH; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA FRAGMENTATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROSARCOMA; HUMANS; MALE; MICE; MICE, INBRED BALB C; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OLIGOPEPTIDES; P-GLYCOPROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33745604930     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Miyazaki K, Kobayashi M, Natsume T, Gondo M, Mikami T, Sakakibara K and Tsukagoshi S: Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem Pharm Bull 43: 1706-1718, 1995.
2. Pettit GR, Kamano Y, Herald CL et al: The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 109: 6883-6885, 1987.
3. Kobayashi M, Natsume T, Tamaoki S, Watanabe J, Asano H, Mikami T, Miyasaka K, Miyazaki K, Gondo M, Sakakibara K and Tsukagoshi S: Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 88: 316-327, 1997.
4. Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K and Kobayashi M: Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Jpn J Cancer Res 91: 737-747, 2000.
5. Natsume T, Koh Y, Kobayashi M, Fukumoto H, Takahashi F, Nakamura T, Ohe Y, Saijo N and Nishio K: Enhanced antitumor activities of TZT-1027 against TNF-α or IL-6 secreting Lewis lung carcinoma in vivo. Cancer Chemother Pharmacol 49: 35-47, 2002.
6. Watanabe J, Natsume T, Fujio N, Miyasaka K and Kobayashi M: Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis 5: 345-353, 2000.
7. Otani M, Natsume T, Watanabe J, Kobayashi M, Murakoshi M, Mikami T and Nakayama T: TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 91: 837-844, 2000.
8. Kobayashi M, Natsume T, Watanabe J, Fujio N, Mikami T, Miyazaki K and Tsukagoshi S: Activity of a novel antitumor agent, TZT-1027. Nippon Yakurigaku Zasshi (Japanese) 114 Suppl: 230-235, 1999.
9. Niitani H, Hasegawa K, Furuse K, Fukuoka M, Horikoshi N and Kudoh S: Phase I studies of TZT-1027, a novel inhibitor of tubulin polymerization [abstract 360]. Proc 10th NCI-EORTC Symposium on New Drug in Cancer Therapy, 1998.
10. Horti J, Juhasz E and Bodrogi I: Preliminary results of a phase I trial of TZT-1027, an inhibitor of tubulin polymerization, in patients with advanced non-small cell lung cancer [abstract 2744]. Proc Am Assoc Cancer Res, 2002.
11. Horti J, Juhasz E, Bodrogi I and Ikeda S: A phase I trial of TZT-1027, an inhibitor of tubulin polymerization, in patients with advanced non-small cell lung cancer (NSCLC) [abstract 256]. Proc AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, 2003.
12. Yamamoto N, Andoh M, Kawahara M, Fukuoka M and Niitani H: Phase I study of TZT-1027, an inhibitor of tubulin polymerization, given weekly x 3 as a 1-hour intravenous infusion in patients (pts) with solid tumors [abstract 420]. Proc Am Soc Clin Oncol, 2002.
13. Scfoeffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, Ganser A, Jenner A, Cheverton P, Wanders J, Oguma T, Atsumi R and Satomi M: Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 15: 671-679, 2004.
14. De Jonge MJA, Van der Gaast A, Planting AST, Van Doorn L, Lems A, Boot I, Wanders J, Satomi M and Verweij J: Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 11: 3806-3813, 2005.
15. Ozawa S, Sugiyama Y, Mitsuhashi J and Inaba M: Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. Cancer Res 49: 3823-3828, 1989.
16. Ishii M, Iwahana M, Mitsui I, Minami M, Imagawa S, Tohgo A and Ejima A: Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. Anticancer Drugs 11: 353-362, 2000.
17. Shionoya M, Jimbo T, Kitagawa M, Soga T and Tohgo A: DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 94: 459-466, 2003.
18. Ochi Y, Minami M and Tohgo A: The orally effective taxane DJ-927 has little ability to induce drug resistance in human non-small cell lung cancer cells. Eur J Cancer Suppl 2: 161, 2004.
19. Miller DW, Fontain M, Kolar C and Lawson T: The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett 107: 301-306, 1996.
20. Anderson KM, Alrefai WA, Anderson CA, Ho Y, Jadko S, Ou D, Wu YB and Harris JE: A response of Panc-1 cells to cisplatinum, assessed with a cDNA array. Anticancer Res 22: 75-81, 2002.
21. Inaba M, Mitsuhashi J and Ozawa S: Kinetic analysis of 5-fluorouracil action against various cancer cells. Jpn J Cancer Res 85: 187-193, 1994.
22. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
23. Fujita F, Fujita M, Taguchi T, Shimozuma K, Sakamoto Y, Kimoto Y et al: Multifactorial analysis of parameters influencing chemosensitivity of human cancer xenografts in nude mice. Int J Cancer 43: 637-644, 1989.